Synendos Therapeutics

Switzerland
Allschwil, Basel-Landschaft, Switzerland, 4123

Company profile

Synendos Therapeutics company profile

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2019-04-01, Month

Headquarters

Postal code
4123
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
6
Total equity funding
$48.2M
Last funding
Grant / 2025-09-01
Last equity funding
Series A / $26.2M
Investors
11
Lead investors
5
Founders
3
Articles
20

Founders and investors

Founders

Andrea ChiccaJurg GertschSimon Russell

Lead investors

InnosuisseKurma PartnersSunstone Life Science VenturesVenture KickYsios Capital

Investors

HTGF (High-Tech Gruenderfonds)Kurma PartnersVenture KickYsios CapitalZürcher Kantonal Bank